132470-83-8

Usage

Uses

Used in Pharmaceutical Industry:
4-Trifluoromethyl-pyridine-2-carbaldehyde serves as a key intermediate in the synthesis of various pharmaceuticals, leveraging its unique structural features to contribute to the development of new drugs. Its presence in the molecular structure can influence the pharmacological properties of the final drug products, enhancing their efficacy and selectivity.
Used in Organic Chemistry:
In the realm of organic chemistry, 4-Trifluoromethyl-pyridine-2-carbaldehyde is utilized as a building block for the synthesis of a wide range of organic compounds. Its reactivity and functional groups make it a valuable component in the creation of complex organic molecules for various applications, including materials science and specialty chemicals.
It is crucial to handle and store 4-Trifluoromethyl-pyridine-2-carbaldehyde with care to mitigate the risks associated with its hazardous nature. Proper safety measures should be implemented to ensure the well-being of individuals involved in its production, use, and disposal.

InChI:InChI=1/C7H4F3NO/c8-7(9,10)5-1-2-11-6(3-5)4-12/h1-4H

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 175205-81-9 2-bromo-4-(trifluoromethyl)pyridine 
• 1401100-81-9 4-(trifluoromethyl)-2-vinylpyridine 
• 588702-62-9 4-(trifluoromethyl)-2-pyridinecarboxylic acid 
• 131747-39-2 [4-(trifluoromethyl)pyridin-2-yl]methyl acetate 
• 131748-17-9 4-Trifluoromethyl-2-picoline-N-oxide 
• 81565-18-6 2-chloro-4-trifluoromethyl pyridine 
• 131747-46-1 (4-trifluoromethyl-pyridin-2-yl)-methanol 

Downstream Products

• 131747-46-1 (4-trifluoromethyl-pyridin-2-yl)-methanol 
• 215867-87-1 2-(chloromethyl)-4-(trifluoromethyl)pyridine 
• 108337-81-1 2,6-dimethyl-4-(4-trifluoromethyl-2-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester 

Relevant academic research and scientific papers

ANALOGS OF 2-PRALIDOXIME AS ANTIDOTES AGAINST ORGANOPHOSPHORUS NERVE AGENTS

Provided herein are compounds useful in treating exposure to an organophosphorus compound, such as a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, such as sarin. Compositions, e.g. pharmaceutical compositions or dosage forms, comprising the compounds also are provided herein. Methods of treating a patient exposed to a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, e.g., an organophosphorus compound, such as sarin, also are provided.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Synthesis method of 2-pyridylaldehyde derivative

The invention relates to the field of medical intermediates, in particular to a synthesis method of 2-pyridylaldehyde derivative. A synthesis path shown in the formula 1 is adopted, wherein X can be Cl or Br or CF3. Cheap starting raw materials are adopted, the use of hazardous materials which have large toxicity and are easily explosive is avoided, the cost of the product is greatly lowered, popularization and industrialized production are facilitated, and the synthesis method has the advantages of being low in cost, easy to operate, high in yield, easy to industrialize and the like. The formula 1 is shown in the description.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I) or pharmaceutically acceptable salts thereof. (Formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.